21.42
-0.87(-3.90%)
Currency In USD
| Previous Close | 22.29 |
| Open | 22.2 |
| Day High | 22.4 |
| Day Low | 21.05 |
| 52-Week High | 23.77 |
| 52-Week Low | 10.57 |
| Volume | 1.62M |
| Average Volume | 1.67M |
| Market Cap | 3.34B |
| PE | -7.34 |
| EPS | -2.92 |
| Moving Average 50 Days | 18.79 |
| Moving Average 200 Days | 16.05 |
| Change | -0.87 |
If you invested $1000 in Denali Therapeutics Inc. (DNLI) since IPO date, it would be worth $998.6 as of February 26, 2026 at a share price of $21.42. Whereas If you bought $1000 worth of Denali Therapeutics Inc. (DNLI) shares 5 years ago, it would be worth $298.33 as of February 26, 2026 at a share price of $21.42.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™
GlobeNewswire Inc.
Feb 05, 2026 7:00 PM GMT
Analysis from continued follow-up of Phase 1/2 clinical trial data in Hunter syndrome (MPS II) reinforces potential for tividenofusp alfa (DNL310) to address full disease spectrumLaunch readiness established in anticipation of April 5, 2026, Prescrip
Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™
GlobeNewswire Inc.
Feb 02, 2026 1:00 PM GMT
SOUTH SAN FRANCISCO, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that management will host a live webcast to review presentations on its Enzyme TransportVehicle™ (ETV) programs at the upcoming 2
Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium™
GlobeNewswire Inc.
Jan 29, 2026 9:00 PM GMT
Hunter syndrome (MPS II) presentations will include analysis from continued follow-up of Phase 1/2 data for tividenofusp alfa (DNL310), currently under FDA Priority ReviewPreliminary data from Phase 1/2 study of DNL126 (ETV:SGSH) for Sanfilippo syndr